Short Communication | Published:

Mesenchymal stem cell: a new horizon in cancer gene therapy

Cancer Gene Therapy volume 23, pages 285286 (2016) | Download Citation

Abstract

Cancer is one of the main problems in public health worldwide. Despite rapid advances in the diagnosis and treatment of cancer, the efficacy of current treatment strategies is still limited. There are promising new results in animal models whereby mesenchymal stem cells (MSCs) can be used as vehicles for targeted therapies. The use of MSCs as therapeutic biological vehicles in cell therapy has several advantages, including immune-silence, tumor tropism, easy and rapid isolation, ex vivo expansion, multilineage differentiation and the capacity to deliver a number of therapeutic agents. Some studies have shown that the microenvironment of the tumor provides a preferential niche for homing and survival of MSCs. Here, we have highlighted various applications of MSCs in cancer gene therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Application of mesenchymal stem cells in melanoma: a potential therapeutic strategy for delivery of targeted agents. Curr Med Chem 2015; 23: 455–463.

  2. 2.

    , . Stem cells as vectors for antitumour therapy. Thorax 2010; 65: 362–369.

  3. 3.

    , , , , , et al. Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. Stem Cells Dev 2012; 21: 2355–2363.

  4. 4.

    , , , , . Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther 2010; 1: 25.

  5. 5.

    , , . Mesenchymal stem cells as vectors for lung cancer therapy. Respiration 2013; 85: 443–451.

  6. 6.

    , , , , , et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model. Gene Ther 2008; 15: 1446–1453.

  7. 7.

    , , , , , et al. Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. Mol Ther 2015; 23: 235–243.

  8. 8.

    , , , , . Engineering toxin‐resistant therapeutic stem cells to treat brain tumors. Stem Cells 2015; 33: 589–600.

  9. 9.

    , , , , , et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004; 11: 1155–1164.

  10. 10.

    , , , . Murine bone marrow–derived mesenchymal stem cells as vehicles for interleukin‐12 gene delivery into Ewing sarcoma tumors. Cancer 2009; 115: 13–22.

Download references

Author information

Affiliations

  1. Hepatitis Research Center and Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran

    • M Mohammadi
  2. Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

    • M R Jaafari
  3. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    • H R Mirzaei
  4. Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    • H Mirzaei

Authors

  1. Search for M Mohammadi in:

  2. Search for M R Jaafari in:

  3. Search for H R Mirzaei in:

  4. Search for H Mirzaei in:

Competing interests

The authors declare no conflict of interest.

Corresponding authors

Correspondence to H R Mirzaei or H Mirzaei.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/cgt.2016.35

Further reading